1. Home
  2. BCDA vs STRR Comparison

BCDA vs STRR Comparison

Compare BCDA & STRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • STRR
  • Stock Information
  • Founded
  • BCDA N/A
  • STRR 1985
  • Country
  • BCDA United States
  • STRR United States
  • Employees
  • BCDA N/A
  • STRR N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • BCDA Health Care
  • STRR Health Care
  • Exchange
  • BCDA Nasdaq
  • STRR Nasdaq
  • Market Cap
  • BCDA 7.9M
  • STRR 7.0M
  • IPO Year
  • BCDA N/A
  • STRR N/A
  • Fundamental
  • Price
  • BCDA $2.54
  • STRR $2.15
  • Analyst Decision
  • BCDA Strong Buy
  • STRR
  • Analyst Count
  • BCDA 1
  • STRR 0
  • Target Price
  • BCDA $25.00
  • STRR N/A
  • AVG Volume (30 Days)
  • BCDA 54.1K
  • STRR 9.5K
  • Earning Date
  • BCDA 03-26-2025
  • STRR 03-21-2025
  • Dividend Yield
  • BCDA N/A
  • STRR N/A
  • EPS Growth
  • BCDA N/A
  • STRR N/A
  • EPS
  • BCDA N/A
  • STRR N/A
  • Revenue
  • BCDA $71,000.00
  • STRR $50,375,000.00
  • Revenue This Year
  • BCDA N/A
  • STRR $15.58
  • Revenue Next Year
  • BCDA N/A
  • STRR $36.27
  • P/E Ratio
  • BCDA N/A
  • STRR N/A
  • Revenue Growth
  • BCDA N/A
  • STRR 2.22
  • 52 Week Low
  • BCDA $0.32
  • STRR $2.05
  • 52 Week High
  • BCDA $5.70
  • STRR $5.35
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 56.72
  • STRR 44.43
  • Support Level
  • BCDA $2.12
  • STRR $2.05
  • Resistance Level
  • BCDA $2.73
  • STRR $2.24
  • Average True Range (ATR)
  • BCDA 0.22
  • STRR 0.09
  • MACD
  • BCDA 0.03
  • STRR 0.01
  • Stochastic Oscillator
  • BCDA 58.21
  • STRR 27.27

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About STRR Star Equity Holdings Inc.

Star Equity Holdings Inc is a multi-industry diversified holding company with two segments: The construction segment manufactures modular housing units for commercial and residential applications. It operates in two businesses: modular building manufacturing and structural wall panel and wood foundation manufacturing, including building supply retail operations, and The investments segment holds corporate-owned real estate, which currently includes two manufacturing facilities in Maine that it leases back to KBS and manufacturing facility. The company derives maximum revenue from Construction Segment.

Share on Social Networks: